Asaren is a technology company.
Asaren has raised $8.0M across 1 funding round.
Asaren has raised $8.0M in total across 1 funding round.
Asa Ren is an Indonesian biotech company specializing in AI-powered precision medicine and clinical-genomic analytics. It builds a digital biobank and bioinformatics platform offering pharmacogenomics and oncogenomics reports to support personalized treatments, drug discovery, and healthcare decision-making for clinicians, researchers, regulators, and over 10,000 users.[1][2] Serving primarily the healthcare sector with a focus on diverse Asian populations, Asa Ren addresses gaps in clinico-genomic data dominated by Caucasian-centric databases, enabling predictions of treatment performance and life-saving discoveries through real-world evidence and 21,000 committed research samples.[2][3] Founded in 2016 in Jakarta, it raised $8.15M before being acquired by Diagnos Laboratories in March 2024, marking strong growth in digital health and AI.[1]
Asa Ren was founded in 2016 in Jakarta, Indonesia, by CEO Aloysius Lian, who leads its focus on AI-driven healthcare insights tailored to Asian demographics.[1][3] The idea emerged from recognizing the need for clinico-genomic databases representing diverse Asian populations, unlike global ones centered on Caucasians, to advance drug discovery and personalized medicine in underserved regions.[3] Early traction built through partnerships like the Oneasa Biobank project with Indonesian hospital groups and clinicians, amassing 21,000 research samples and scaling to thousands of monthly users.[2][3] A pivotal push came from international expansion efforts, such as collaborating with freelancers for Japan market entry—Japan's advanced pharma sector and status as the world's second-largest healthcare market—to secure knowledge transfer and sponsorships.[3]
Asa Ren rides the AI in digital health wave, particularly precision medicine and genomics, amid booming demand for personalized treatments in Asia's underserved markets.[1][2] Timing aligns with Japan's mature pharma ecosystem and Indonesia's rising HealthTech adoption, where genomic research lags but offers high growth potential—Japan's market scale provides validation and partnerships for knowledge transfer.[3] Market forces like real-world evidence needs, diverse population data gaps, and AI infrastructure advancements favor it, positioning Asa Ren to influence Southeast Asia's startup ecosystem by strengthening local biobanks and clinician tools post-acquisition.[1][3] Its inclusion in CB Insights' Digital Health and AI collections underscores its role in global tech-enabled healthcare transformation.[1]
Post-2024 acquisition by Diagnos Laboratories, Asa Ren will likely deepen synergies in service expansion, leveraging combined strengths for broader healthcare impact and new revenue from AI-genomics.[1] Trends like AI-driven drug discovery, Asia-centric real-world evidence, and Japan-Indonesia collaborations will shape its path, potentially accelerating the Oneasa Biobank and pharma sponsorships.[2][3] Influence may evolve from niche innovator to regional leader in precision medicine, enhancing Diagnos's position while unlocking personalized treatments for millions—echoing its origins as a "secret book" to minimize health risks and maximize potential.[4]
Asaren has raised $8.0M in total across 1 funding round.
Asaren's investors include Accel, Caffeinated Capital, Hercules Capital, Insight Partners, Khosla Ventures, Prosperity7 Ventures, Sound Ventures, Top Harvest Capital, Upside Partnership, Y Combinator, George Hoyem, Janis Krums.
Asaren has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $8.0M Seed | Accel, Caffeinated Capital, Hercules Capital, Insight Partners, Khosla Ventures, Prosperity7 Ventures, Sound Ventures, Top Harvest Capital, Upside Partnership, Y Combinator, George Hoyem, Janis Krums, Karl Jacob, Roger Ehrenberg, Ron Garret, Sam Altman, Tom McInerney |